Horizon Pharma PLC (NASDAQ:HZNP) gapped up before the market opened on Friday . The stock had previously closed at $13.88, but opened at $13.99. Horizon Pharma PLC shares last traded at $13.66, with a volume of 1,040,906 shares changing hands.

A number of equities research analysts have recently weighed in on the stock. Jefferies Group LLC reissued a “buy” rating and set a $16.00 price objective on shares of Horizon Pharma PLC in a report on Thursday. Cowen and Company reissued a “buy” rating on shares of Horizon Pharma PLC in a report on Thursday, September 28th. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Horizon Pharma PLC in a report on Thursday, September 28th. They set a “buy” rating and a $16.00 price objective on the stock. Cantor Fitzgerald reissued a “buy” rating and set a $17.00 price objective on shares of Horizon Pharma PLC in a report on Tuesday, September 26th. Finally, Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma PLC and gave the company a “buy” rating in a report on Sunday, September 10th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $18.00.

The company’s 50 day moving average is $13.00 and its 200-day moving average is $12.75. The firm’s market cap is $2.21 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. During the same period last year, the firm posted $0.56 EPS. Horizon Pharma PLC’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts anticipate that Horizon Pharma PLC will post $1.07 EPS for the current year.

A number of institutional investors have recently modified their holdings of HZNP. Bank of Montreal Can boosted its holdings in shares of Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 1,378 shares in the last quarter. Sheaff Brock Investment Advisors LLC boosted its holdings in shares of Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 500 shares in the last quarter. Family Management Corp purchased a new stake in shares of Horizon Pharma PLC in the second quarter valued at about $131,000. Ballentine Partners LLC purchased a new stake in shares of Horizon Pharma PLC in the second quarter valued at about $139,000. Finally, Massachusetts Financial Services Co. MA purchased a new stake in shares of Horizon Pharma PLC in the first quarter valued at about $151,000. 82.33% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/08/horizon-pharma-plc-hznp-shares-gap-up-to-13-99.html.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.